Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Rare YKT6 Gene Variants Linked to New Neurological Disorder

A recent collaborative study has discovered rare variants in the YKT6 gene as the cause of a new neurological disorder characterized by developmental delays along with severe progressive liver disease and a potential risk for liver cancer.

2 Apr 2024

New Breakthrough in Generative AI Models and AlphaFold Structures for Drug Discovery

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has achieved a significant breakthrough in the application of multiple generative AI models and AlphaFold structures for drug discovery.

3 Aug 2023

New Genetic Marker Could Predict Lenvatinib Resistance in Hepatocellular Carcinoma

A genetic marker discovered by UT Southwestern Medical Center researchers could help physicians predict which patients with hepatocellular carcinoma are most likely to develop resistance to the drug lenvatinib.

23 Jun 2023

Proteomics Approach Identifies p62-Mediated Selective Autophagy of the Supramolecular Vault Complex

Our body functioning is delicately balanced between the synthesis and breakdown of various cellular components.

16 May 2023

Small Vesicles Originating From Intestinal Bacteria Have an Adverse Effect on the Liver

Researchers from Niigata University and Kyoto Prefectural University have revealed that small vesicles, around 100 nm in size, released by intestinal bacteria induce immune activation and progression of liver cirrhosis, as well as reduction of serum albumin level, subsequently leading to edema and ascites.

19 Apr 2023

Iron-dependent cell death can be used to improve immunotherapies against liver cancer

Iron-dependent cell death (ferroptosis) is a type of programmed cell death by means of which the body kills off diseased, defective or superfluous cells.

20 Feb 2023

Molecular staple: The DNA repair mechanism impeding cancer treatment

Due to the continuous cellular activity, malfunctions frequently occur, making error-correcting systems crucial for cells. However, it serves the cancer cells’ best interests to cause errors when it comes to destroying them.

30 Jan 2023

Rare and protective loss-of-function mutations offer possible NAFLD drug targets

A significant genome-wide association study on the nonalcoholic fatty liver disease (NAFLD) has just been published in Nature Genetics by researchers from Amgen subsidiary deCODE Genetics.

26 Oct 2022

Study identifies novel targets for treating sorafenib-resistant hepatocellular carcinoma

Research headed by Professor Xiujun Cai used the CRISPR/cas9 system to screen the entire genome of hepatocellular carcinoma cells (HepG2) under sorafenib treatment.

25 Apr 2022

Study identifies new targets for treating sorafenib-resistant hepatocellular carcinoma using CRISPR-Cas9 screening

This study is led by Xiujun Cai (Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine). Professor Xiujun Cai's research team screened the whole genome of hepatocellular carcinoma cells (HepG2) through CRISPR / cas9 system under sorafenib treatment, and screened the dominant gene in sorafenib resistance.

20 Apr 2022

Coffee found to have a stimulating effect on some digestive processes

A new scientific review, published in Nutrients, highlights coffee's effects on digestion and the gut, and its impact on organs involved in digestion.

19 Jan 2022

Research describes dynamic genomic landscape of tumor heterogeneity in hepatocellular carcinoma

Clinician scientists and scientists from the National Cancer Centre Singapore and A*STAR's Genome Institute of Singapore, in collaboration with Singapore General Hospital, the National University Health System, Duke-NUS Medical School, Nanyang Technological University, and collaborators from China, Malaysia, Thailand and the Philippines, have described a dynamic genomic landscape of tumour heterogeneity in hepatocellular carcinoma (HCC).

13 Dec 2021

Targeting Shp2 as a cancer therapy may worsen the disease

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyrosine phosphatase 2 or more briefly, Shp2.

10 Nov 2021

Understanding molecular determinants of liver cancer in patients with Indigenous American ancestry

Oncotarget published "Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry" which reported that contrasting with this pattern, the age structure of HCC in Andean people displays a bimodal distribution with half of the patients developing HCC in adolescence and early adulthood.

2 Jun 2021

Diet plays a crucial role in liver disease outcome, mouse model shows

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD patients are at higher risk of developing Non-alcoholic steatohepatitis (NASH), which causes severe and chronic liver inflammation, fibrosis and liver damage.

2 Jun 2021

Dietary supplement helps to partially prevent fatty liver disease in rats

A recent study by researchers at the University of Jyväskylä was successful in partially preventing fatty liver disease in rats.

5 Nov 2020

Reducing food intake can reduce risk of liver cancer caused by fatty liver

Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan. In order to change this unfortunate state of affairs, it is important to improve the prognosis of non-alcoholic fatty liver disease.

2 Nov 2020

Oncopig fulfills the unmet clinical modeling needs for hepatocellular carcinoma

Volume 11, Issue 28 of Oncotarget features "Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation" by Gaba et, al. which reported that reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs.

12 Oct 2020

Human genetics: New insights into our own biology

Who are we? Where did we come from? How did we get here? Throughout the ages, humans have sought answers to these questions, pursuing wisdom through religion, philosophy, and eventually science.

21 Sep 2020

Antibodies from natural controllers appear to play crucial role in eliminating hepatitis B virus

Infections in humans caused by the hepatitis B virus (HBV) represent a major public health problem. Despite the availability of effective protective vaccines, more than 250 million individuals worldwide are chronically infected according to WHO estimates.

From Institut Pasteur 14 Aug 2020